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Cardiostim is a congress dedicated to devices, interventional electrophysiology and non-
invasive electrophysiology. It was born in 1978, and imagined by Dr Jacques Mugica for
educational purposes, and is held traditionally in Nice, French Riviera, on even years. This
2010 edition had 5700 participants coming from 92 countries. A large Japanese attendance
was present and two joint sessions were organized with the Japanese Heart Rhythm Society.
The program was divided into three sections: updates, education, and presentations based
on selected submitted abstracts.
Following is a summary of these selected abstracts, which does reﬂect the trends of our
specialty, and of technological advances. For devices, telemedicine, MRI compatibility, full
automaticity were the main topics. In cardiac pacing, respect of spontaneous AV conduction
is conﬁrmed as being essential, and positioning of the right ventricular lead remains an issue.
For ICDs, better deﬁnition of candidates, utility of DFT testing, and reduction in inappropriate
shocks are the main concerns. In CRT, extension of indications toward earlier stages of HF,
implementation of hemodynamic sensors, and new approaches to the left ventricle are at the
ﬁrst row.
Ablation techniques beneﬁt from new technologies: interest and limits of cryo-ablation,
new radio-frequency catheters, visualization of ablative lesions, contact control, and use of
imaging techniques. The goals are: to speed up procedures, make them safer, and more
eﬃcient.
(J Arrhythmia 2010; 26: 277–284)
1. Device technologies
1.1 Telemedicine for cardiac pacing and ICDs
All manufacturers conceived a remote monitor-
ing system for ICD recipients, but only one pro-
poses such a facility for the whole range of its
production.
1.1.1 The COMPAS trial
This study (presented by Mabo) is the ﬁrst
prospective randomized trial including 538 patients:
- One group is active (with telecardiology
On), followed up with telemedicine during
18 months;
- In the standard group, with conventional
face to face follow-up, telemedicine is
passive, the investigator being blind with
no accessibility to the transmitted data.
The study demonstrates the non-inferiority of
telemedicine compared to conventional follow-up,
with a rate of severe adverse events of 17.3% in the
active group versus 19.1% in the standard group.
Furthermore, the number of patients’ visits is
reduced by 27% in the active group. Telecardiology
allowed the early diagnosis of various abnormalities,
especially persistent atrial ﬁbrillation.
For the ﬁrst time, COMPAS demonstrates that
telecardiology is a reliable alternative to traditional
follow-up in paced patients.
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1.1.2 Centralized telecardiology
Vogtmann presents his original experience of
centralized telecardiology, MoniC, in which 9
satellite centers oﬀer their data to a collecting
center. A specialized nurse, trained to the use of
the system, receives all alerts, and classify them
according to a pre-established algorithm in urgent
(immediate call to a doctor), relevant (information
given to the satellite center), or without subsequent
action. Over one year, 121 patients implanted with
pacemakers or ICDs were followed up. 1.3 report/
patient/an was issued to the satellite center; among
these, 36.8% triggered a clinical action (device
reprogramming, change in the drug treatment,
hospitalization). The nurse workload was 25.6min/
100 days of follow-up per patient, and 7.4min of
communication with the satellite centers.
1.1.3 What are the advantages of device remote
follow-up?
In the study from Ceb, gathering 267 events in
paced patients, the main observed clinical event was
atrial ﬁbrillation, detected more rapidly with tele-
medicine. An earlier visit induced by the diagnosis
of AF, leaded to a change in the drug treatment in
86.5% (antithrombotic agents, antiarrhythmic drugs,
reprogramming, cardioversion). Conclusions from
Lacopino are comparable in a population of 104
patients implanted with an ICD, followed with the
Carelink system: 32% patients with AF during a
one-year follow-up (25% of episodes being asymp-
tomatic). AF was managed much earlier (cardiover-
sion, His-bundle ablation, pulmonary vein ablation).
Telecardiology might be an eﬃcient tool for
surveys, with early alerts. Any recall means a lot
of workload for the implanting center personnel:
Schwartz had to manage 13 alerts from 2000 to
2008, in 278 patients out of the 1051 patients im-
planted with an ICD during that period. A tele-
monitoring would have been a better option, more
eﬃcient, less expensive. These results are conﬁrmed
in the subgroup of 40 patients of the E-COST study,
who were implanted with the Sprint Fidelis lead.
Over 22 months of follow-up, 4 lead failures have
been suspected from noise detection and/or abrupt
change in lead impedance. The diagnosis was
conﬁrmed in 3 cases, leading to the lead replacement
before occurrence of inappropriate shocks.
In the ALTITUDE study, using the Latitude
system, Gillian retrospectively analyzed the data
from 15991 patients and showed that programming
of a high VF zone and of a VT zone is associated
with a low risk of inappropriate shocks.
1.2 MRI and pacemakers/ICDs
MRI use is contraindicated in PM/ICD recipients.
The risks are the following: over/under sensing,
device dysfunction, life-threatening arrhythmias.
However, manufacturers are now able to provide
MRI compatible devices.
Sommer gives the results of a multicentric study
about 464 randomized patients and followed over 1
year. Among them, 258 underwent a 1.5 Tesla MRI
(spinal chord, brain). No complication occurred
during the examination. Anelli Monti also reports a
study of 41 pacemaker patients who underwent an
MRI without any complication. The MRI compatible
leads are stiﬀer, and a higher rate of complication has
been noticed, leading to reintervention in 14.6%cases.
MRI compatibility is a step forward, but the
system should be used under special conditions:
- Manual pre- and post-reprogramming is
necessary, a procedure which might be
practically diﬃcult;
- Only new patients are concerned. The
whole system should be compatible: pace-
maker and leads.
The 3 tesla MRI will soon be the standard: will
our PMs be still compatible?
1.3 The new standard of connection: IS4 con-
nector
The IS4 standard was announced since years but
is still not available. This connection is supposed
to replace the IS1/DF1 connection. Doshi reports a
primary experience of 53 mono- and dual-coil ICD
leads according to the IS4 draft from June 2009.
The complication rate and the electrical character-
istics are not diﬀerent from the IS1 standard. Eckardt
evaluated the performances of mono- and dual-coil
leads, with active or passive ﬁxation in 419 patients.
Nothing special was noticed when leads are tested
with high energy shocks (41 joules), sensing of
ventricular arrhythmias is normal as pacing thresh-
olds and impedances are. No sensing abnormality
was observed during manipulations of the can
through the skin.
To implant a pacemaker and to avoid ventricular
pacing may look paradoxical. But preservation of
AV conduction algorithms are appropriate when
AV conduction is normal or subnormal. However,
post-operative prescription of antiarrhythmic drugs
and long PR intervals, longer than 300ms, are two
conditions where AV conduction may impair rapidly
in the mid-term follow-up (Mabo).
1.4 Anticoagulation and device implantation
Patients who require implantation of a device,
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who are at risk of hemorrhage or thrombosis be-
cause of their pathologies, and who need anti-
platelet or anticoagulant therapy, are very numerous.
Rodriguez-Manero compared the continuation of
anticoagulation (INR between 1.7 and 2.3) with
the use of low-weight heparin in 175 consecutive
patients. No thrombo-embolic complication occur-
red. A lower rate of hemorrhagic complications was
observed (16.3% versus 26.5%) in the anticoagulated
group, especially major hemorrhages (3.2% versus
6.1%) with shorter hospitalizations (1.3 days versus
1.8).
To decrease the rate of hemorrhagic complica-
tions, Ohlow tested the D-Stat ﬂowable haemostat,
an association of collagen and thrombin in the form
of a powder, placed in the device pocket at the end of
implantation in 156 patients under antiplatelet or
anticoagulation treatment. The rate of complication
was not modiﬁed, but a trend for more reinterven-
tions (7.3 versus 2.7%), and more infections (4.9
versus 1.4%) was noticed.
2. Deﬁbrillation
Presentations are mostly devoted to ICDs com-
plications, and the search for solutions. However,
one must not forget the main beneﬁt of ICDs: they
save lives everyday!
2.1 Beneﬁts are obvious
In a meta-analysis gathering results from 8 clinical
trials and 5343 patients with EF less than 35%,
Theuns shows a 60% reduction in arrhythmia related
deaths, and 28% reduction in total mortality, in
patients with (29%) or without ischemic cardio-
myopathy (26%). The LOHCAT trial from Van
Rees demonstrates that the majority of the 750 pa-
tients surviving from sudden cardiac death received
an appropriate therapy from their device, whatever
their ejection fraction was: 65% if EF < 40% versus
63% if EF > 40%. However, patients with very low
EF are not good candidates for ICD therapy as
recalled by Van Rees: among 900 ischemic patients,
EF less than 25% and high age are associated with a
bad prognosis. Wakslak, in a multivariate analysis of
the 1232 patients of the MADIT II trial, reports a
37% reduction in mortality when renal function is
normal. However, the beneﬁt is not signiﬁcant in
patients more than 75 years of age, and when the
renal function is impaired (uremia > 2:5 g/l). In the
ACT register, Deering gathered data from 6129
patients, followed over 2 years, and found a mortal-
ity rate of 8.9%, with 4.9% of non cardiac deaths and
1.1% of sudden cardiac deaths. The highest mortality
rate was found in the oldest patients with low EF,
large QRS, presence of AF, high NYHA class, and
implantation of a CRT device.
The national Swedish registry (Gadler) has 3997
implanted patients with a survival rate of 80% at 5
years, and 58% at 10 years. But the survival rates of
the implanted ICD and leads are respectively 63%
and 96% at 5, and 8%/87% at 10 years. Lifetime of
the battery is shorter in case of a CRT device (3.5
years). Devices with autocapture feature should have
a longer lifetime. Today, the automatic threshold
measurement functions properly as demonstrated
by Beau, who analyzed the manual and automatic
results of atrial, RV, and LV threshold tests in 107
ICD patients.
Nageh shows that the prognosis of patients im-
planted for secondary prevention (before or after
heart surgery) is less favorable: 37% total mortality
rate at 50 months, and 27% in the 95 patients who
received appropriate therapies.
2.2 Type of leads
Debate is still on-going about the use of mono-
and dual-coil leads. Shah shows that dual coil leads
should be avoided in infants and teenagers (78
patients): eﬃcacy is not diﬀerent but the risk of
deterioration is higher.
The same debate is about the location of the lead
within the right ventricle. The SEPTAL trial (Mabo)
compared the medioseptal (n ¼ 97) versus the apical
ICD lead position (n ¼ 98). Over a 3-year follow-up,
no diﬀerence was observed between the two groups
in terms of therapy eﬃciency and complication rate.
2.3 Should we perform a deﬁbrillation test at
implant?
The tradition is to test deﬁbrillation at two
attempts with a 10 Joule safety. However, the test
gives a probability of eﬃcacy, and does not
guarantee shock eﬃciency afterwards, and on the
other hand, leads have improved and maximal energy
shock available has been increased (40 joules instead
of 31 Joules). Chances of success are enhanced.
In the observational PANORAMA study
(Sweidan), 43% of the 1377 patients were not tested
at implant, especially CRT devices (63% versus 24%
for the single chamber devices, and 44% for the dual
chamber). Primary prevention implants were less
tested (50% versus 72% tested in secondary pre-
vention implants). When a test was performed, the
shock was unique in 81% cases, with a safety margin
less than 10 joules in 78%. The FIRST registry
(Mansourati) brought similar conclusions, with 29%
not tested among 298 patients, and in 63% cases,
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with only one test. The SAFE-ICD study (Brignole)
including 2096 patients have similar results with
59% not tested, the main reason being the NYHA
class (II) in a multivariate analysis.
Does it change the prognosis?
Greenberg (ACT registry) included 4680 ICD
recipients, and 24.3% patients were not tested. These
patients have a higher mortality but due to non
cardiac over mortality. The sudden cardiac death rate
is not diﬀerent. The same conclusions are given by
Kusnitz, in 231 patients with the same mortality
rate at 20 months of follow-up (9.6% if tested
versus 9.6% if not tested). Hojgaard recalls that an
eﬃcient shock is not a warranty of shocks eﬃcacy
during follow-up: among the 216 patients of the
COGENT-4 study, 3 had ineﬃcient shocks although
high energy shock devices with short charge times
were used. In these 3 recipients, tests at implant were
eﬃcient.
Some medications may inﬂuence eﬃcacy unfav-
orably, like amiodarone which decreases safety
margin. As a matter of fact, under amiodarone,
Stiller demonstrates a mean increase of 4 joules in
38 patients, superior to 10 joules in 7, and a not
warranted eﬃcacy in 4 (10%).
2.4 Achilles’ heels of ICDs
In 787 patients, El-Damaty reports 18% of
inappropriate shocks over a 3.6-year follow-up, and
Grimma, a 12% rate in 805 patients over 49 months.
After 5 years, Van Rees gives a cumulative inci-
dence of 18%, favored by previous AF, age less than
70 years, and absence of statine treatment. Inappro-
priate shocks are associated with an over mortality
in multivariate analysis (RR: 1.6). In 699 patients
studied by Contractor, treated (412) or not (287) with
statines, there is a reduction in the number of shocks
(OR:1.64) with statines. The misclassiﬁcation of
atrial arrhythmias is higher with single chamber
devices. Analysis of atrial signals between the supe-
rior vena cava and the ICD can could be an option.
Several abstracts reveal the failure rate of the
Sprint Fidelis lead. The Danish registry (Johansen)
gathers 601 leads, with a 15.8% failure rate after 54
months for the single coil leads, and 12.7% for the
dual coil leads. Only 1.7% leads were not functional
at the end of follow-up. In 196 patients, Patwala
reports a 16% lead fracture rate, which increases
over time. The largest series comes from Hauser on
1039 leads, with an increasing failure rate over time,
up to 14% at 50 months. Young age, female gender,
high EF, and presence of a cardiomyopathy (hyper-
trophic especially), are factors of higher failure rate
in an univariate analysis. Medtronic has developed
an algorithm capable of reducing the inappropriate
rate due to oversensing of artifacts, without delaying
the detection of the true arrhythmias (Meijer). The
Lead integrity Alert has been tested by Kallinen
showing a reduction in occurrence (18% versus
69%) and number of inappropriate shocks (0.5%
versus 8.4%).
2.5 Arrhythmic storms
They impose an urgent hospitalization. Pastor
found 7% storms in 632 patients during a 40-month
follow-up. The predictive factor revealed by a
multivariate analysis was implantation for secondary
prevention.
3. Cardiac resynchronization therapy
The last part of year 2009 is characterized by
the publications of MADIT-CRT and REVERSE
(European cohort), that triggered the new CRT
guidelines, with extension of indications to NYHA
class II patients. This Cardiostim edition focused on
the subgroups analysis of MADIT-CRT.
3.1 Come back on MADIT-CRT
These studies revealed, for MADIT-CRT, a
reduction in the adverse HF events by CRT-D
devices in mildly symptomatic patients (NYHA class
I or II), with LV dysfunction (EF < 30%), and large
QRS (>120ms), and for REVERSE, a beneﬁcial
eﬀect of CRT (and not deﬁbrillation) on LV
remodeling in a similar population (NYHA class I
or II, EF < 40% and QRS > 110ms).
Zareba shows the superiority of CRT when LBBB
is present, and QRS > 160ms, in the 1820 patients
of MADIT-CRT. Arshad observed a better eﬀect of
CRT in women, who demonstrate a lower all cause
mortality. In ischemic patients, Barsheshet shows
that the beneﬁcial eﬀect of CRT increases over time
in patients with prior infarction, and is better in
ischemic patients without infarction. Last but not
least, occurrence of atrial arrhythmias is associated
with a bad prognosis (mortality and HF events).
Among 1089 patients followed for 2.4 years, 16.5%
patients experienced atrial arrhythmias.
Eyal Nof reveals that the proportion of paced
patients requiring an upgrading to CRT is low,
around 5% during a 26-month follow-up. Lesaux
shows that in the 60 patients presenting with mild
LV dysfunction, receiving a primary prevention
ICD, none of them had to be upgraded to CRT after
3 years. For Scott, the upgrading rate to CRT in ICD
patients with EF < 35% is 7%, with rates of 0.5%,
3.6%, and 10.1% at 1, 3 and 5 years respectively.
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3.2 Factors inﬂuencing the outcome of CRT
patients
The higher the grade of mitral insuﬃciency, the
poorer the prognosis for Kenji Ando. However
reduction of moderate to severe MI is a factor of
good prognosis.
As already reported in MADIT-CRT, occurrence
of atrial arrhythmias had a poor prognosis. Santini
reports the results of the Italian registry gathering
1193 patients from 77 centers. After a follow-up of
13 months, the incidence of atrial arrhythmias was
30%. Their occurrence was correlated with higher
rates of death, heart transplant, and HF hospital-
izations. Results of the ACTION-HF registry, re-
ported by Botto have similar results.
Chronic obstructive pulmonary disease is a factor
of poor prognosis in CRT patients.
In 611 patients included over a 10-year period,
with a follow-up of 40 months, Lunati reports a 5%
mortality rate. Eyal Nof, showing similar results,
found that the clinical response at one year is
predictive of the long term survival, but not the
echographic response.
For Muto, the presence of a contractile reserve
at stress echo is predictive of the CRT response. In
271 patients, 78% responders are observed when
there is a contractile reserve versus 54%. In 126
patients of Neja’s study, rates are respectively 75%
and 35%.
3.3 And the super responders?!
Foster observed 25% super responders in MADIT-
CRT. Factors of super response are: Female gender,
non-ischemic cardiomyopathy, and very large QRS.
However, Stefan found only 5% of super responders
with similar favorable factors. Defaye had 18%
super responders in his cohort of 340 patients, with a
survival rate of 65% at 5 years.
3.4 A lot of excitement about hemodynamic
sensors
- Peak endocardial acceleration
The results of the CLEAR study given by Ritter
are now available. When the Peak Endocardial
Acceleration sensor (SonR) is used to set AV and
VV intervals, the response rate is 86% versus 62%
in conventional practice. Mabo demonstrates that
analysis of the two components of SonR (PEA1 and
PEA2) allow prediction of the patient’s HF status,
and Donal shows a good correlation between systolic
time intervals given by SonR in comparison with
echo. Bordachar shows in a pig experiment, that
dP/dt max can be well analyzed from a SonR
lead placed in the atrium. Last but not least, Klug
suggests the appropriateness of the SonR amplitude
changes during VTs for analysis of their tolerance.
- Transvalvular and intra-thoracic impedance
Neri found a nice correlation between transvalv-
ular impedance and hemodynamic variations in
patients implanted. Pandozi evaluated impedance
variations during rhythm disorders, and found a
correlation between signal changes and hemody-
namic tolerance. Its use could avoid inappropriate
shocks in ICD patients. Transvalvular impedance
could also allow detection of aggravation of heart
failure. Wiegand reported the results of the InSync
Sentry registry including 896 patients: 78% patients
who had an alert from their device, presented signs
of heart failure. Inappropriate alerts were otherwise
corrected by reprogramming of the alert threshold.
3.5 Technological advances
Implantation of a LV lead in the coronary sinus
network remains challenging. Gutleben and Goetze
suggest that 3D reconstruction could help the im-
plant procedure. In addition smaller leads were
developed (Exner, Wong) to facilitate the catheter-
ization of small diameter veins, as well as new tools
(Giannola). The interest of the electronic reposition-
ing was reported by several presentations (Defaye,
Gold, Huizar): choice is directed by the best thresh-
old, the absence of phrenic nerve stimulation, or
better sensing capability. Introduction of quadripolar
leads will even enhance the reprogramming capa-
bilities (Danschel, Thibault).
Last but not least, new approaches to the left
ventricle are under development. Mihalez reports the
endocardial LV trans-apical approach in 14 patients.
A conventional active ﬁxation lead is placed endo-
cardially after puncture of the LV apex at the latero-
basal wall. These techniques allow endocardial
pacing that has been demonstrated as being hemo-
dynamically more eﬃcient and less dependent from
the position of the lead in animal experiments. Strik
report an experiment on 6 dogs with a signiﬁcant
improvement of electrical activation, and systolic
and diastolic function compared to epicardial pacing.
4. Electrophysiology, ablation techniques
Atrial ﬁbrillation ablation is still the main topic
of this section. However, ventricular ablation tech-
niques becomes a major issue in this ﬁeld.
4.1 Management of syncopes
It remains diﬃcult and patients undergo many
examinations ending up with a transfer to the
cardiology department with the diagnosis of unex-
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plained syncope. Special syncope units should
improve the management of syncope in our hospi-
tals. The multicentric PICTURE study (Edvadsson)
is the typical example of what’s going on: the
majority of patients were visited by 3 diﬀerent
specialists and underwent a mean number of 13
examinations. This fact enhances the role of the
REVEAL system that demonstrates the cardiac
origin of syncope in 84% leading to the implantation
of a pacemaker or an ICD.
Favale analyzed the interest of the tilt test. In 20%
cases, the test was positive. Independent risk factors
were found: female gender, more than 3 syncope
episodes before diagnosis, and a positive tilt test.
4.2 Management of sudden cardiac death: a
status quo
A Swiss registry (Katz) reveals a survival rate
of 6.4% only. The majority of survivors presented
sudden cardiac death in presence of witnesses who
started CPR. This CPR was especially beneﬁcial
when witnesses had been trained to it (52% of
survivors), and when the origin of SCD was
arrhythmic (82% of survivors).
The early repolarization syndrome was studied by
3 groups. A Greek registry (Dilaveris) revealed
this syndrome in 5% of the overall population. The
Bordeaux team, which has been the pioneer, ana-
lyzed the QRS fragmentation to predict the occur-
rence of ventricular arrhythmias in 44 patients with
abnormal EKG, and prior SCD. Over a 5.5-year
follow-up, a recurrence of ventricular rhythm dis-
orders occurred in 71% patients presenting with QRS
fragmentation versus no recurrence when QRS frag-
mentation was absent. Last but not least, a Fin team
(Tikkanen) found that early repolarization found in
lateral leads, was frequently associated with hyper-
trophic cardiomyopathy and metabolic syndrome.
4.3 Research and new techniques
Several groups study the use of stem cells in
various conditions.
In the dilated cardiomyopathy, Vrtovec studied
the eﬀects of the intra-coronary injection of stem
cells on ventricular repolarization: results are en-
couraging, with a signiﬁcant improvement in func-
tional, biological, and echographic criteria, without
modiﬁcation of the QT interval.
In the ischemic heart disease, Krause evaluated
the eﬀect of cellular transplant in patients with
myocardial infarction that occurred 10 days earlier,
with impaired EF. EF improved without occur-
rence of ventricular arrhythmias during a 6-month
follow-up.
In the ischemic cardiomyopathy with heart failure,
Romanov succeeded in reducing cardiac mortality at
one year, with improvement of ventricular function.
Salvarani studied the arrhythmogenicity induced
by stem cells transplantation, a drawback that limits
the expansion of the technique so far. The TGF-b1
growing factor seems to be part of the phenomenon.
So far, trials are small sized, but are the start of
larger studies, which are mandatory for the develop-
ment of this new line of techniques.
4.4 Ablation of ventricular rhythm disorders
Three abstracts are of interest in this ﬁeld.
Amin evaluated the eﬀect of the infarct zone size
on the success of VT ablation. When the ﬁbrotic
zone is small (deﬁned as <35 cm2 on a CARTO
voltage map), the chances of success are important
and the risk of recurrence minimal.
Maury prefers the VT ablation (versus ICD) in
patients with recurrent VTs, severe cardiomyopathy,
and multiple comorbidities. This discussion will
occur frequently in the future with the ageing of the
population.
Jadidi characterizes the arrhythmogenic substrate
of VF: heterogeneous tissular abnormalities were
found in the Purkinje network, but also dispersion of
action potential durations, triggering reentry phe-
nomena.
4.5 Atrial ﬁbrillation is everywhere
4.5.1 Some genetics
Boldt studied in atrial ﬁbrillation the implication
of the GATA4 factor mutations, known for being
responsible for congenital heart diseases. In 96
patients with idiopathic AF, two mutations of the
GATA4 factor were found.
4.5.2 AF and medical treatment
Several meta-analyses followed AFFIRM, and
conﬁrmed that ventricular rate control was as good
as maintenance of sinus rhythm as far as mortality
is concerned. However, Bonanno, who included
the most recent studies in his meta-analysis demon-
strates that maintenance if sinus rhythm oﬀers a
reduction in cardiovascular mortality. In the same
way, a Japanese study (Matsuda) conﬁrms the
superiority of sinus rhythm on LV EF and absence
of dyssynchrony (2D speckle tracking).
4.5.3 A new predictive tool of AF recurrence: atrial
Doppler tissue imaging (PA-TDI)
Two teams evaluated this new parameter, which
seems to be a good independent predictive parameter
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of the recurrence of AF in HF patients and in the
acute phase of myocardial infarction. Management
of AF is crucial in this patient population as the
increased risk of mortality is well known in case
of AF occurrence during follow-up.
4.5.4 Which ablation strategy for which AF?
Ablation of persistent AF is feasible but with
less success than for paroxysmal AF. In the former
population, isolation/deconnection of pulmonary
veins is not suﬃcient. Patients should be better
stratiﬁed as suggested by Barker, because they
compose a heterogeneous group of patients.
The most frequent procedure is to apply additional
left atrial lines of ablation to the pulmonary vein
isolation; It increases the success rate: 44% versus
49% in a series of 142 patients (Berkowitch). 66% of
patients without recurrence of AF during follow-up
went back to sinus rhythm during the ablation
procedure. These lines were done at the LA roof,
septum, along the coronary sinus, and in the mitral
isthmus. The drawback is that those lines may be
incomplete, and thus, responsible for occurrence of
left atrial ﬂutters (fourfold more than without lines
(Berkowitch).
The other possible technique is to locate the
LA zones where fragmented potentials are recorded
(complex atrial fractioned electrograms, CAFE), and
that may trigger AF recurrence. Seitz reports a corre-
lation between these zones, revealed by CARTO,
and zones of ﬁbrosis analyzed by late enhancement
MRI. Their surface area are correlated with the rate
of early recurrence of AF (Daccarett). However,
these latter ﬁndings are contradictory with those of
Jadidi. The MRI ﬁbrotic zones would correspond to
low voltage electrograms in sinus rhythm, and not to
CAFE that would be functional only.
Four presentations (Yamane, Yao, Matsuo,
Maeda) deal with the use of ATP for testing the
reconnection of pulmonary veins at the end of the
ablation procedure (10 to 20%). Last but not least, in
order to avoid the rare but catastrophic complication
of esophageal ﬁstula, Rolf and Fu¨rnkranz propose
the use of a temperature probe placed in the
esophagus during the ablation procedure, for the
permanent monitoring of esophageal temperature
and to modulate the energy of applications.
4.5.5 A constellation of new technologies
- Cryoablation: where are we?
This is the ﬁrst alternative technique to ‘‘hot’’ AF
ablation. Results are comparable in ablation for
paroxysmal/persistent AF. In series from 55 to
776 patients, Heintz, Nadji, Schumacher, Kane, and
Haldfass report short term success rates of 85–95%.
After 3 to 12 months of follow-up, 52 to 97%
patients remain without symptomatic AF. The
anatomical approach of the cryoablation for AF
can be combined with the traditional electrical check
of pulmonary vein deconnection. In that case, the
success rate increases at 6 months (86% versus 53%,
Koch). Compared to the ‘‘hot’’ technique, procedure
duration is close to 150min, but X-Ray exposure is
increased (35min, mean value). The main com-
plication is a reversible phrenic nerve standstill
(7–10%). Risks of thrombo-embolism and tampo-
nade are comparable. Long term vein stenosis is not
absent (Langbein), and the cryo-balloon should be
kept at the antrum of the veins, and not placed within
veins. However in case of complementary radio-
frequency ablation within the veins, this risk goes up
to 4% (Mouquet). In conclusion, cryoablation for
ablation of paroxysmal AF is an eﬃcient technique
that is proposed at ﬁrst row by Kane. However, there
is no reliable data supporting its indication in
persistent/permanent AF.
- New ablation catheters
Ablation Frontiers has catheters designed for
an anatomical and electrophysiological approach.
They are multipurpose, circular, linear or star shaped
(PVAC, MAAC, and MASC), and allow application
of radiofrequency at several spots in mono or bipolar
mode. Their clinical eﬃcacy looks similar to the
traditional catheter designs. After a 6- to 12-month
follow up, 50 to 85% patients remain in sinus
rhythm, depending on the type of AF, persistent or
paroxysmal (Mulder, Zeb, Bu¨nz, Bulava). Type
and rate of complications are also the same as in
the conventional approaches. Procedure duration is
much shorter (Klein, Chung), similar to the duration
of cryo-ablation procedures, but X-ray exposure
is more important as ﬂuo is the only tool to guide
navigation.
A better contact of the catheter tip on the
myocardial wall creates a more complete and trans-
mural lesion, but with a higher risk of perforation.
Endosense has developed the TactiCath, which
enables real-time measurement of the force applied
by the catheter to the tissue. In the TOCCATA study,
Neuzil showed the inverse relationship between
the measured contact force and the AF recurrence
rate. The dynamic systolic and diastolic variability of
contact depends on the ablation site within the left
atrium, the catheter orientation, and the possible use
of steerable sheaths (Herrera, Shah). This feature is
also essential to prevent perforations. The Therapy
Cool Flex from St Jude Medical is an irrigated
catheter with a ﬂexible tip. In experiments, it has
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been demonstrated that this catheter allows a larger
contact surface with the myocardial wall, with an
identical contact force (Byrd), and a better and
deeper dispersion of energy within the tissue, with
a lower surface temperature (Narciso). Voyage
Medical developed the IRIS catheter, with a new
irrigation system (saline bridge), and allows the
direct visualization of the ablated endocardium. The
continuity of the ablation lines can be controlled
in real-time, as shown by Sacher in 10 patients with
an indication of cavo-tricuspid isthmus ablation.
In experiments, Chik observed larger and deeper
lesions, obtained with less energy power. Last but
not least, the EAS balloon (Cardiofocus) has been
tested in 21 patients (Schmidt) in a feasibility and
safety study. It has a variable diameter with an
endoscope that allows visualization of venous ostia.
The laser energy is used for ablation. Fluo times are
similar to conventional procedures, 98% veins are
isolated, one tamponade was reported.
- Robotic magnetic navigation
Stereotaxis proposes the NIOBE system, includ-
ing a very ﬂexible, non-traumatic and irrigated
catheter that can be controlled remotely. This system
allows the parallel use of electro-anatomical maps
(Biosense, Carto). In a series of 446 patients,
randomized in 2 groups (magnetic versus manual
navigation), Bauerfeld shows that, whatever the
indication for ablation can be, the remote magnetic
navigation oﬀer similar success rates, with much less
X-ray exposure, and a signiﬁcantly lower complica-
tion rate (0.5 versus 2.6%). However, Arya reports
less enthusiastic results as far as AF ablation is
concerned: a complete pulmonary vein deconnection
is obtained in only 79% cases versus 87% with the
manual procedure. At 6 months, 58% patients have
no AF recurrence versus 66%. Carmo suggests that
the catheter tip might be too ﬂexible, and as a matter
of fact, the application time of energy to achieve
deconnection of pulmonary veins is signiﬁcantly
shorter when a more powerful magnetic ﬁeld of 0.1 T
(instead of 0.08 T) is used.
4.6 Some nice case reports
The one from Borbola evaluating the beneﬁts
of ivabradine in inappropriate sinus tachycardias,
that has not the side eﬀects of beta-blockers, nor the
complications of ablation.
The one from Cantu, who describes a VT ablation
via a trans-apical approach in a patient with mitral
and aortic mechanical valves.
The one from Maury, who ablated an atrial ﬂutter/
AF in a patient having a Heart Mate II, but without
any navigation system to avoid interferences.
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